The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

Early-phase clinical trials, those first-in-human studies, are where years of research and millions in investment meet the unpredictable reality of human biology.

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a ...

Recent Trends and Patient Outcomes of Phase I Trials: A Single-Institution Experience in the Era of New Therapeutic Agents This study reviewed all industry-sponsored phase I clinical trial protocols ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

BASEL, Switzerland--(BUSINESS WIRE)--Indivi, an independent TechBio company, today announced the closing of a CHF15 million financial investment round led by Ava Investors. The additional financial ...